Real-world efficacy of postoperative adjuvant EGFR-TKI therapy for stage IA2-IA3 lung adenocarcinoma with high-risk pathological factors.

ABSTRACT:

Background

The role of EGFR-TKIs as adjuvant therapy for stage IA lung adenocarcinoma after surgery remains controversial. Though 5-year OS of stage IA patients reaches 88%, the 5-year DFSs of IA1, IA2, and IA3 vary a lot, 88.2%, 73.6% and 64.5%, respectively. This study specifically evaluated the clinical efficacy of postoperative EGFR-TKI therapy in stage IA2-IA3 lung adenocarcinoma patients with high-risk pathological factors.

Methods

Stage IA2-IA3 lung adenocarcinoma patients with high-risk pathological factors at Jinling Hospital from January 1, 2017 to December 31, 2021 were collected. Eligible patients were grouped into EGFR-TKI therapy group and non-EGFR-TKI therapy group. Subgroup analysis was performed to explore potential benefits of adjuvant EGFR-TKI therapy.

SUBMITTER: Lu S 

PROVIDER: S-EPMC12577173 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature